MDxHealth SA

MDxHealth SA is a commercial-stage precision diagnostics company, which engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. It operates through the following geographical segments: United States of America, The Netherlands, Belgium, Spain, Poland, Italy, Rest of EU, and Rest of the World. The firm offers ConfirmMDx, SelectMDx, AssureMDx, InformMDx, SelectMDx, and MonitorMDx. The company was founded by Herman Spolders and Philip S. Devine on January 10, 2003 and is headquartered in Herstal, Belgium.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

MDxHealth reports strong Q2 revenue growth and operational improvements

MDxHealth's Q2 2024 performance reflects robust revenue growth, driven by increased test volumes and improved margins.
The company's strategic focus on revenue drivers and operational efficiency has led to a reduction in operating losses.
While facing challenges in a competitive market, MDxHealth is well-positioned to capitalize on growth opportunities and deliver strong results.

MDxHealth reports robust Q1 growth, eyes urology expansion opportunities

MDxHealth delivered strong financial performance in Q1 2025, with revenue and gross profit showing significant growth. While challenges like increased net loss exist, the company's focus on sustained growth and disciplined financial management is evident. Exploring opportunities in the urology space and maintaining growth momentum are key priorities for MDxHealth moving forward.

MDxHealth reports robust Q3 performance and eyes growth opportunities

MDxHealth's Q3 results reflect strong revenue growth, improved operational efficiency, and a focus on customer-centric strategies. While challenges like net loss and operating loss persist, opportunities from the ExoDx acquisition integration and sales team expansion are promising. The company's financial position remains stable with cash reserves for future investments, positioning it well for sustainable growth and value creation.

MDxHealth reports robust Q4 performance amidst rising expenses and losses

MDxHealth's Q4 2025 performance showcased strong revenue growth and operational efficiency, despite challenges in operating and net losses. The company's emphasis on sustaining top-line growth and improving profitability presents opportunities for future success. Strategic cost management and operational enhancements will be key to achieving the targeted EBITDA margin of 10% by year-end. Investors should monitor MDxHealth's progress in addressing challenges and capitalizing on growth opportunities for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MDxHealth SA is a commercial-stage precision diagnostics company, which engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. It operates through the following geographical segments: United States of America, Europe and Rest of the World. The firm offers ConfirmMDx, SelectMDx, AssureMDx, InformMDx, SelectMDx, and MonitorMDx. The company was founded by Herman Spolders and Philip S. Devine on January 10, 2003 and is headquartered in Herstal, Belgium.